Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 23.32M P/E - EPS this Y - Ern Qtrly Grth -
Income -3.04M Forward P/E - EPS next Y - 50D Avg Chg 4.00%
Sales 196.44k PEG - EPS past 5Y - 200D Avg Chg 32.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -23.00%
Recommedations - Quick Ratio 0.59 Shares Outstanding 76.65M 52W Low Chg 150.00%
Insider Own 14.23% ROA -150.84% Shares Float 60.80M Beta -0.40
Inst Own 0.02% ROE - Shares Shorted/Prior -/- Price 0.33
Gross Margin - Profit Margin - Avg. Volume 5,937 Target Price -
Oper. Margin -1,302.28% Earnings Date Jul 11 Volume 3,000 Change -4.55%
About DIAGNOS INC

DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.

DIAGNOS INC News
04/16/24 DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
04/12/24 AI & Technology Hybrid Investor Conference Agenda: Presentations Now Available for Online Viewing
04/09/24 AI & Technology Hybrid Investor Conference Presented by Water Tower Research Agenda Announced for April 10 and 11
04/09/24 DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
04/03/24 DIAGNOS Announces Grant of Stock Options
04/02/24 DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
03/22/24 DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
03/01/24 DIAGNOS Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
02/29/24 DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
02/27/24 DIAGNOS Announces Closing of First Tranche of Private Placement
02/23/24 Diagnos Announces Variation in One Insider Ownership of Common Shares
02/21/24 DIAGNOS recognized as a Top TSX Venture Exchange Company
01/16/24 DIAGNOS Appoints New Chief Operating Officer
12/11/23 DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care
12/04/23 DIAGNOS Announces Closing of Private Placement
10/05/23 DIAGNOS AI Retina Analysis is being deployed across Canada’s Largest Specialist Care Provider in Diabetes & Endocrinology
05/18/23 DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants
05/17/23 DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of “IRIS-ai powered by DIAGNOS”